Roadmap for the next generation of Children's Oncology Group rhabdomyosarcoma trials

被引：1

作者：

Metts, Jonathan L. ^{[1
,2
]}

Aye, Jamie M. ^{[3
]}

Crane, Jacquelyn N. ^{[4
,5
]}

Oberoi, Sapna ^{[6
,7
]}

Balis, Frank M. ^{[4
]}

Bhatia, Smita ^{[8
]}

Bona, Kira ^{[9
,10
]}

Carleton, Bruce ^{[11
]}

Dasgupta, Roshni ^{[12
]}

Dela Cruz, Filemon S. ^{[13
]}

Greenzang, Katie A. ^{[9
,10
]}

Kaufman, Jonathan L. ^{[14
,15
]}

Linardic, Corinne M. ^{[16
,17
]}

Parsons, Susan K. ^{[18
,19
]}

Robertson-Tessi, Mark ^{[20
]}

Rudzinski, Erin R. ^{[21
,22
]}

Soragni, Alice ^{[23
,24
]}

Stewart, Elizabeth ^{[25
]}

Weigel, Brenda J. ^{[26
]}

Wolden, Suzanne L. ^{[27
]}

Weiss, Aaron R. ^{[28
]}

Venkatramani, Rajkumar ^{[29
]}

Heske, Christine M. ^{[30
]}

机构：

[1] Moffitt Comprehens Canc Ctr, Sarcoma Dept, Tampa, FL USA

[2] Johns Hopkins All Childrens Hosp, Canc & Blood Disorders Inst, St Petersburg, FL USA

[3] Univ Alabama Birmingham, Dept Pediat, Div Pediat Hematol & Oncol, Birmingham, AL USA

[4] Childrens Hosp Philadelphia, Div Oncol, Philadelphia, PA USA

[5] Univ Penn, Abramson Canc Ctr, Perelman Sch Med, Dept Pediat, Philadelphia, PA USA

[6] Canc Care Manitoba, Dept Pediat Hematol & Oncol, Winnipeg, MB, Canada

[7] Univ Manitoba, Dept Pediat & Child Hlth, Winnipeg, MB, Canada

[8] Univ Alabama Birmingham, Inst Canc Outcomes & Survivorship, Heersink Sch Med, Birmingham, AL USA

[9] Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA USA

[10] Dana Farber Canc Inst, Div Populat Sci, Boston, MA USA

[11] Univ British Columbia, Fac Med, Dept Pediat, Div Translat Therapeut, Vancouver, BC, Canada

[12] Univ Cincinnati, Cincinnati Childrens Hosp Med Ctr, Div Pediat Gen & Thorac Surg, Cincinnati, OH 45221 USA

[13] Mem Sloan Kettering Canc Ctr, Dept Pediat, New York, NY USA

[14] Emory Univ, Dept Hematol & Med Oncol, Atlanta, GA USA

[15] Patient Advocacy Comm, Childrens Oncol Grp, Monrovia, CA USA

[16] Duke Univ, Sch Med, Dept Pediat, Durham, NC USA

[17] Duke Univ, Sch Med, Dept Pharmacol & Canc Biol, Durham, NC USA

[18] Tufts Med Ctr, Inst Clin Res & Hlth Policy Studies, Boston, MA USA

[19] Tufts Med Ctr, Div Hematol Oncol, Boston, MA USA

[20] H Lee Moffitt Canc Ctr & Res Inst, Integrated Math Oncol Dept, Tampa, FL USA

[21] Seattle Childrens Hosp, Dept Lab Med & Pathol, Seattle, WA USA

[22] Univ Washington, Med Ctr, Seattle, WA USA

[23] Univ Calif Los Angeles, Dept Orthopaed Surg, Los Angeles, CA USA

[24] Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Los Angeles, CA USA

[25] St Jude Childrens Res Hosp, Dept Oncol, Memphis, TN USA

[26] Univ Minnesota, Div Pediat Hematol & Oncol, Minneapolis, MN USA

[27] Mem Sloan Kettering Canc Ctr, Dept Radiat Oncol, New York, NY USA

[28] Maine Med Ctr, Dept Pediat, Portland, ME USA

[29] Baylor Coll Med, Texas Childrens Canc Ctr, Houston, TX USA

[30] NCI, Pediat Oncol Branch, Ctr Canc Res, Bethesda, MD USA

来源：

CANCER | 2024年 / 130卷 / 22期

关键词：

clinical trials; novel agents; pediatric; quality of life; rhabdomyosarcoma; PATIENT-REPORTED OUTCOMES; TISSUE SARCOMA COMMITTEE; RISK RHABDOMYOSARCOMA; PEDIATRIC-PATIENTS; 1ST RELAPSE; RADIOTHERAPY; VINCRISTINE; THERAPY; CLASSIFICATION; IMPLEMENTATION;

D O I：

10.1002/cncr.35457

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Clinical trials conducted by the Intergroup Rhabdomyosarcoma (RMS) Study Group and the Children's Oncology Group have been pivotal to establishing current standards for diagnosis and therapy for RMS. Recent advancements in understanding the biology and clinical behavior of RMS have led to more nuanced approaches to diagnosis, risk stratification, and treatment. The complexities introduced by these advancements, coupled with the rarity of RMS, pose challenges to conducting large-scale phase 3 clinical trials to evaluate new treatment strategies for RMS. Given these challenges, systematic planning of future clinical trials in RMS is paramount to address pertinent questions regarding the therapeutic efficacy of drugs, biomarkers of response, treatment-related toxicity, and patient quality of life. Herein, the authors outline the proposed strategic approach of the Children's Oncology Group Soft Tissue Sarcoma Committee to the next generation of RMS clinical trials, focusing on five themes: improved novel agent identification and preclinical to clinical translation, more efficient trial development and implementation, expanded opportunities for knowledge generation during trials, therapeutic toxicity reduction and quality of life, and patient engagement.

引用

页码：3785 / 3796

页数：12

共 93 条

[1] Circulating Tumor DNA Is Prognostic in Intermediate-Risk Rhabdomyosarcoma: A Report From the Children's Oncology Group [J].

Abbou, Samuel ;

Klega, Kelly ;

Tsuji, Junko ;

Tanhaemami, Mohammad ;

Hall, David ;

Barkauskas, Donald A. A. ;

Krailo, Mark D. D. ;

Cibulskis, Carrie ;

Nag, Anwesha ;

Thorner, Aaron R. R. ;

Pollock, Samuel ;

Imamovic-Tuco, Alma ;

Shern, Jack F. F. ;

DuBois, Steven G. G. ;

Venkatramani, Rajkumar ;

Hawkins, Douglas S. S. ;

Crompton, Brian D. D. .

JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (13) :2382-+

[2] Imaging of pediatric extremity soft tissue tumors: A COG Diagnostic Imaging Committee/SPR Oncology Committee White Paper [J].

Acord, Michael Richard ;

Pace, Erika ;

El-Ali, Alexander ;

Chaturvedi, Apeksha ;

Iyer, Ramesh S. ;

Navarro, Oscar M. ;

Pandit-Taskar, Neeta ;

Parikh, Ashishkumar K. ;

Schechter, Ann ;

Shaikh, Raja ;

McCarville, M. Beth .

PEDIATRIC BLOOD & CANCER, 2023, 70

[3] Phase I trial of Ganitumab plus Dasatinib to Cotarget the Insulin-Like Growth Factor 1 Receptor and Src Family Kinase YES in Rhabdomyosarcoma [J].

Akshintala, Srivandana ;

Sundby, R. Taylor ;

Bernstein, Donna ;

Glod, John W. ;

Kaplan, Rosandra N. ;

Yohe, Marielle E. ;

Gross, Andrea M. ;

Derdak, Joanne ;

Lei, Haiyan ;

Pan, Alexander ;

Dombi, Eva ;

Palacio-Yance, Isabel ;

Herrera, Kailey R. ;

Miettinen, Markku M. ;

Chen, Helen X. ;

Steinberg, Seth M. ;

Helman, Lee J. ;

Mascarenhas, Leo ;

Widemann, Brigitte C. ;

Navid, Fariba ;

Shern, Jack F. ;

Heske, Christine M. .

CLINICAL CANCER RESEARCH, 2023, 29 (17) :3329-3339

[4] Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update [J].

Amstutz, Ursula ;

Henricks, Linda M. ;

Offer, Steven M. ;

Barbarino, Julia ;

Schellens, Jan H. M. ;

Swen, Jesse J. ;

Klein, Teri E. ;

McLeod, Howard L. ;

Caudle, Kelly E. ;

Diasio, Robert B. ;

Schwab, Matthias .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 2018, 103 (02) :210-216

[5] Vincristine, Actinomycin, and Cyclophosphamide Compared With Vincristine, Actinomycin, and Cyclophosphamide Alternating With Vincristine, Topotecan, and Cyclophosphamide for Intermediate-Risk Rhabdomyosarcoma: Children's Oncology Group Study D9803 [J].

Arndt, Carola A. S. ;

Stoner, Julie A. ;

Hawkins, Douglas S. ;

Rodeberg, David A. ;

Hayes-Jordan, Andrea A. ;

Paidas, Charles N. ;

Parham, David M. ;

Teot, Lisa A. ;

Wharam, Moody D. ;

Breneman, John C. ;

Donaldson, Sarah S. ;

Anderson, James R. ;

Meyer, William H. .

JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (31) :5182-5188

[6] Vincristine dosing, drug exposure and therapeutic drug monitoring in neonate and infant cancer patients [J].

Barnett, Shelby ;

Hellmann, Farina ;

Parke, Elizabeth ;

Makin, Guy ;

Tweddle, Deborah A. ;

Osborne, Caroline ;

Hempel, Georg ;

Veal, Gareth J. .

EUROPEAN JOURNAL OF CANCER, 2022, 164 :127-136

[7] Pharmacokinetics and Pharmacogenetics of Cyclophosphamide in a Neonate and Infant Childhood Cancer Patient Population [J].

Barnett, Shelby ;

Errington, Julie ;

Sludden, Julieann ;

Jamieson, David ;

Poinsignon, Vianney ;

Paci, Angelo ;

Veal, Gareth J. .

PHARMACEUTICALS, 2021, 14 (03)

[8] Symptom Monitoring With Patient-Reported Outcomes During Routine Cancer Treatment: A Randomized Controlled Trial [J].

Basch, Ethan ;

Deal, Allison M. ;

Kris, Mark G. ;

Scher, Howard I. ;

Hudis, Clifford A. ;

Sabbatini, Paul ;

Rogak, Lauren ;

Bennett, Antonia V. ;

Dueck, Amylou C. ;

Atkinson, Thomas M. ;

Chou, Joanne F. ;

Dulko, Dorothy ;

Sit, Laura ;

Barz, Allison ;

Novotny, Paul ;

Fruscione, Michael ;

Sloan, Jeff A. ;

Schrag, Deborah .

JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (06) :557-+

[9] Overall survival results of a randomized trial assessing patient-reported outcomes for symptom monitoring during routine cancer treatment. [J].

Basch, Ethan M. ;

Deal, Allison Mary ;

Dueck, Amylou C. ;

Bennett, Antonia Vickery ;

Atkinson, Thomas Michael ;

Scher, Howard I. ;

Kris, Mark G. ;

Hudis, Clifford A. ;

Sabbatini, Paul ;

Dulko, Dorothy ;

Rogak, Lauren J. ;

Barz, Allison Emily ;

Schrag, Deborah .

JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (18)

[10] Children's Oncology Group's 2023 blueprint for research: Germ cell tumors [J].

Bhuta, Roma ;

Shah, Rachana ;

Gell, Joanna J. ;

Poynter, Jenny N. ;

Bagrodia, Aditya ;

Dicken, Bryan J. ;

Pashankar, Farzana ;

Frazier, A. Lindsay ;

Shaikh, Furqan .

PEDIATRIC BLOOD & CANCER, 2023, 70

← 1 2 3 4 5 6 7 8 9 10 →